-
Endpoints for randomized controlled clinical trials for COVID-19 treatments
Authors:
Lori E Dodd,
Dean Follmann,
**g Wang,
Franz Koenig,
Lisa L Korn,
Christian Schoergenhofer,
Michael Proschan,
Sally Hunsberger,
Tyler Bonnett,
Mat Makowski,
Drifa Belhadi,
Yeming Wang,
Bin Cao,
France Mentre,
Thomas Jaki
Abstract:
Introduction: Endpoint choice for randomized controlled trials of treatments for COVID-19 is complex. A new disease brings many uncertainties, but trials must start rapidly. COVID-19 is heterogeneous, ranging from mild disease that improves within days to critical disease that can last weeks and can end in death. While improvement in mortality would provide unquestionable evidence about clinical s…
▽ More
Introduction: Endpoint choice for randomized controlled trials of treatments for COVID-19 is complex. A new disease brings many uncertainties, but trials must start rapidly. COVID-19 is heterogeneous, ranging from mild disease that improves within days to critical disease that can last weeks and can end in death. While improvement in mortality would provide unquestionable evidence about clinical significance of a treatment, sample sizes for a study evaluating mortality are large and may be impractical. Furthermore, patient states in between "cure" and "death" represent meaningful distinctions. Clinical severity scores have been proposed as an alternative. However, the appropriate summary measure for severity scores has been the subject of debate, particularly in relating to the uncertainty about the time-course of COVID-19. Outcomes measured at fixed time-points may risk missing the time of clinical benefit. An endpoint such as time-to-improvement (or recovery), avoids the timing problem. However, some have argued that power losses will result from reducing the ordinal scale to a binary state of "recovered" vs "not recovered."
Methods: We evaluate statistical power for possible trial endpoints for COVID-19 treatment trials using simulation models and data from two recent COVID-19 treatment trials.
Results: Power for fixed-time point methods depends heavily on the time selected for evaluation. Time-to-improvement (or recovery) analyses do not specify a time-point. Time-to-event approaches have reasonable statistical power, even when compared to a fixed time-point method evaluated at the optimal time.
Discussion: Time-to-event analyses methods have advantages in the COVID-19 setting, unless the optimal time for evaluating treatment effect is known in advance. Even when the optimal time is known, a time-to-event approach may increase power for interim analyses.
△ Less
Submitted 9 June, 2020;
originally announced June 2020.
-
Efficient model-based Bioequivalence Testing
Authors:
Kathrin Möllenhoff,
Florence Loingeville,
Julie Bertrand,
Thu Thuy Nguyen,
Satish Sharan,
Guoying Sun,
Stella Grosser,
Liang Zhao,
Lanyan Fang,
France Mentré,
Holger Dette
Abstract:
The classical approach to analyze pharmacokinetic (PK) data in bioequivalence studies aiming to compare two different formulations is to perform noncompartmental analysis (NCA) followed by two one-sided tests (TOST). In this regard the PK parameters $AUC$ and $C_{max}$ are obtained for both treatment groups and their geometric mean ratios are considered. According to current guidelines by the U.S.…
▽ More
The classical approach to analyze pharmacokinetic (PK) data in bioequivalence studies aiming to compare two different formulations is to perform noncompartmental analysis (NCA) followed by two one-sided tests (TOST). In this regard the PK parameters $AUC$ and $C_{max}$ are obtained for both treatment groups and their geometric mean ratios are considered. According to current guidelines by the U.S. Food and Drug Administration and the European Medicines Agency the formulations are declared to be sufficiently similar if the $90\%$- confidence interval for these ratios falls between $0.8$ and $1.25$. As NCA is not a reliable approach in case of sparse designs, a model-based alternative has already been proposed for the estimation of $AUC$ and $C_{max}$ using non-linear mixed effects models. Here we propose another, more powerful test than the TOST and demonstrate its superiority through a simulation study both for NCA and model-based approaches. For products with high variability on PK parameters, this method appears to have closer type I errors to the conventionally accepted significance level of $0.05$, suggesting its potential use in situations where conventional bioequivalence analysis is not applicable.
△ Less
Submitted 21 February, 2020;
originally announced February 2020.
-
Protection of hamsters from mortality by reducing fecal moxifloxacin concentration with DAV131A in a model of moxifloxacin-induced Clostridium difficile colitis
Authors:
Charles Burdet,
Sakina Sayah-Jeanne,
Thu Thuy Nguyen,
Christine Miossec,
Nathalie Saint-Lu,
Mark Pulse,
William Weiss,
Antoine Andremont,
France Mentré,
Jean De Gunzburg
Abstract:
BackgroundLowering the gut exposure to antibiotics during treatments can prevent microbiota disruption. We evaluated the effect of an activated charcoal-based adsorbent, DAV131A, on fecal free moxifloxacin concentration and mortality in a hamster model of moxifloxacin-induced C. difficile infection.Methods215 hamsters receiving moxifloxacin subcutaneously (D1-D5) were orally infected at D3 with C.…
▽ More
BackgroundLowering the gut exposure to antibiotics during treatments can prevent microbiota disruption. We evaluated the effect of an activated charcoal-based adsorbent, DAV131A, on fecal free moxifloxacin concentration and mortality in a hamster model of moxifloxacin-induced C. difficile infection.Methods215 hamsters receiving moxifloxacin subcutaneously (D1-D5) were orally infected at D3 with C. difficile spores. They received various doses (0-1800mg/kg/day) and schedules (BID, TID) of DAV131A (D1-D8). Moxifloxacin concentration and C. difficile counts were determined at D3, and mortality at D12. We compared mortality, moxifloxacin concentration and C. difficile counts according to DAV131A regimens, and modelled the link between DAV131A regimen, moxifloxacin concentration and mortality. ResultsAll hamsters that received no DAV131A died, but none of those that received 1800mg/kg/day. A significant dose-dependent relationship between DAV131A dose and (i) mortality rates, (ii) moxifloxacin concentration and (iii) C. difficile counts was evidenced. Mathematical modeling suggested that (i) lowering moxifloxacin concentration at D3, which was 58$μ$g/g (95%CI=50-66) without DAV131A, to 17$μ$g/g (14-21) would reduce mortality by 90% and (ii) this would be achieved with a daily DAV131A dose of 703mg/kg (596-809).ConclusionsIn this model of C. difficile infection, DAV131A reduced mortality in a dose-dependent manner by decreasing fecal free moxifloxacin concentration.
△ Less
Submitted 21 September, 2017;
originally announced September 2017.
-
A pharmacokinetic -- viral kinetic model describes the effect of alisporivir monotherapy or in combination with peg-IFN on 2 hepatitis C virologic response
Authors:
Thi Huyen Tram Nguyen,
France Mentré,
Micha Levi,
**g Yu,
Jérémie Guedj
Abstract:
Alisporivir is a cyclophilin inhibitor with demonstrated in vitro and in vivo activity against hepatitis C 11 virus (HCV). We estimated antiviral effectiveness of alisporivir alone or in combination with 12 pegylated-Inteferon (peg-IFN) in 88 patients infected with different HCV genotypes treated for four 13 weeks. The pharmacokinetics of both drugs were modeled and used as driving functions for t…
▽ More
Alisporivir is a cyclophilin inhibitor with demonstrated in vitro and in vivo activity against hepatitis C 11 virus (HCV). We estimated antiviral effectiveness of alisporivir alone or in combination with 12 pegylated-Inteferon (peg-IFN) in 88 patients infected with different HCV genotypes treated for four 13 weeks. The pharmacokinetics of both drugs were modeled and used as driving functions for the viral 14 kinetic model. Genotype was found to significantly affect pegylated-Inteferon effectiveness ($ε$= 86.3% 15 and 99.1% in genotype-1/4 and genotype-2/3, respectively, p\textless{}10 -7) and infected cells loss rate ($δ$= 16 0.22 vs 0.39 day -1 in genotype-1/4 and genotype-2/3, respectively, p\textless{}10 -6). Alisporivir effectiveness 17 was not significantly different across genotype and was high for doses $\ge$600 mg QD. We simulated 18 virologic responses with other alisporivir dosing regimens in HCV genotype-2/3 patients using the 19 model. Our predictions consistently matched the observed responses, demonstrating that this model 20 could be a useful tool for anticipating virologic response and optimize alisporivir-based therapies.
△ Less
Submitted 17 September, 2015;
originally announced September 2015.
-
Nonlinear Mixed-Effect Models for Prostate-Specific Antigen Kinetics and Link with Survival in the Context of Metastatic Prostate Cancer: a Comparison by Simulation of Two-Stage and Joint Approaches
Authors:
Soléne Desmée,
France Mentré,
Christine Veyrat-Follet,
Jérémie Guedj
Abstract:
In metastatic castration-resistant prostate cancer (mCRPC) clinical trials, the assessment of treatment efficacy essentially relies on the time-to-death and the kinetics of prostate-specific antigen (PSA). Joint modelling has been increasingly used to characterize the relationship between a time-to-event and a biomarker kinetics but numerical difficulties often limit this approach to linear models…
▽ More
In metastatic castration-resistant prostate cancer (mCRPC) clinical trials, the assessment of treatment efficacy essentially relies on the time-to-death and the kinetics of prostate-specific antigen (PSA). Joint modelling has been increasingly used to characterize the relationship between a time-to-event and a biomarker kinetics but numerical difficulties often limit this approach to linear models. Here we evaluated by simulation the capability of a new feature of the Stochastic Approximation Expectation-Maximization algorithm in Monolix to estimate the parameters of a joint model where PSA kinetics was defined by a mechanistic nonlinear mixed-effect model. The design of the study and the parameter values were inspired from one arm of a clinical trial. Increasingly high levels of association between PSA and survival were considered and results were compared with those found using two simplified alternatives to joint model, a two-stage and a joint sequential model. We found that joint model allowed for a precise estimation of all longitudinal and survival parameters. In particular the effect of PSA kinetics on survival could be precisely estimated, regardless of the strength of the association. In contrast, both simplified approaches led to bias on longitudinal parameters and two-stage model systematically underestimated the effect of PSA kinetics on survival.
In summary we showed that joint model can be used to characterize the relationship between a nonlinear kinetics and survival. This opens the way for the use of more complex and physiological models to improve treatment evaluation and prediction in oncology.
△ Less
Submitted 17 March, 2015;
originally announced March 2015.